Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Influenza

Free Subscription Articles published in Antiviral Res Retrieve available abstracts of 163 articles: HTML format

Single Articles

August 2025
1. LUO YS, Shen H, Ling P, Gao H, et al
   Tirofiban protects mice against severe RSV pneumonia by potentially inhibiting platelet activation via the GPIbalpha-vWF pathway.
   Antiviral Res. 2025;240:106207.
   PubMed     Abstract available
   
   
   June 2025
2. HUSSAIN S, Meijer A, Govorkova EA, Dapat C, et al
   Global update on the susceptibilities of influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2020-2023.
   Antiviral Res. 2025 Jun 24:106217. doi: 10.1016/j.antiviral.2025.106217.
   PubMed     Abstract available
   
   
   
3. MARTINEZ-GZEGOZEWSKA Y, Rasmussen L, Nebane NM, McKellip S, et al
   High-throughput screening for identification of Influenza A inhibitors using a cell-based immunofluorescence assay.
   Antiviral Res. 2025 Jun 6:106209. doi: 10.1016/j.antiviral.2025.106209.
   PubMed     Abstract available
   
   
   
4. MALUNE P, Esposito F, Tramontano E
   Unveiling SARS-CoV-2's heart: role, structure and inhibition of SARS-CoV-2 RNA-dependent RNA polymerase.
   Antiviral Res. 2025 Jun 3:106208. doi: 10.1016/j.antiviral.2025.106208.
   PubMed     Abstract available
   
   
   May 2025
5. FAGE C, Loison S, Zwygart AC, Poli R, et al
   Influenza A(H1N1)pdm09 Virus Resistance to Baloxavir, Oseltamivir and Sialic Acid Mimetics in Single and Dual therapies: Insights from Human Airway Epithelia and Murine Models.
   Antiviral Res. 2025 May 3:106174. doi: 10.1016/j.antiviral.2025.106174.
   PubMed     Abstract available
   
   
   
6. TAKASHITA E, Yasui Y, Ikegaya A, Saka K, et al
   Impact of the Polymerase Acidic Protein E199K Substitution in Influenza A Viruses on Baloxavir Susceptibility.
   Antiviral Res. 2025 May 3:106173. doi: 10.1016/j.antiviral.2025.106173.
   PubMed     Abstract available
   
   
   
7. BONNEUX B, Ceconi M, Stobbelaar K, Herschke F, et al
   Insights in the RSV L polymerase function and structure.
   Antiviral Res. 2025;237:106148.
   PubMed     Abstract available
   
   
   March 2025
8. ZHU Y, Gao Z, Feng X, Hu Y, et al
   Comprehensive preclinical characterization of IPB29, a pan-coronavirus fusion inhibitor under clinical trials.
   Antiviral Res. 2025;237:106154.
   PubMed     Abstract available
   
   
   
9. KUO YS, Chiang PC, Kuo CY, Huang CG, et al
   Inhibition of influenza A virus proliferation in mice via universal RNA interference.
   Antiviral Res. 2025 Mar 25:106149. doi: 10.1016/j.antiviral.2025.106149.
   PubMed     Abstract available
   
   
   
10. PADEY B, Droillard C, Duliere V, Fouret J, et al
    Host-targeted repurposed diltiazem enhances the antiviral activity of direct acting antivirals against Influenza A virus and SARS-CoV-2.
    Antiviral Res. 2025 Mar 4:106138. doi: 10.1016/j.antiviral.2025.106138.
    PubMed     Abstract available
    
    
    February 2025
11. BRUN J, Arman BY, Hill ML, Kiappes JL, et al
    Assessment of repurposed compounds against coronaviruses highlights the antiviral broad-spectrum activity of host-targeting iminosugars and confirms the activity of potent directly acting antivirals.
    Antiviral Res. 2025 Feb 23:106123. doi: 10.1016/j.antiviral.2025.106123.
    PubMed     Abstract available
    
    
    
12. ZIAN D, Iaconis D, Nenci S, Crusco A, et al
    The Efficiency of High-Throughput Screening (HTS) and in-silico data analysis during medical emergencies: identification of effective antiviral 3CLpro inhibitors.
    Antiviral Res. 2025 Feb 18:106119. doi: 10.1016/j.antiviral.2025.106119.
    PubMed     Abstract available
    
    
    
13. INOUE A, Ichikawa T, Wada D, Maruyama S, et al
    M49L and other drug resistance mutations emerging in individuals after administration of ensitrelvir in Japanese clinical settings.
    Antiviral Res. 2025;236:106118.
    PubMed     Abstract available
    
    
    
14. TIETJEN I, Kwan DC, Petrich A, Zell R, et al
    Antiviral Mechanisms and Preclinical Evaluation of Amantadine Analogs that Continue to Inhibit Influenza A Viruses with M2(S31N)-Based Drug Resistance.
    Antiviral Res. 2025 Feb 11:106104. doi: 10.1016/j.antiviral.2025.106104.
    PubMed     Abstract available
    
    
    
15. SCHREIBER A, Ludwig S
    Host-targeted antivirals against SARS-CoV-2 in clinical development - Prospect or disappointment?
    Antiviral Res. 2025;235:106101.
    PubMed     Abstract available
    
    
    January 2025
16. UEHARA T, Yotsuyanagi H, Ohmagari N, Doi Y, et al
    Ensitrelvir treatment-emergent amino acid substitutions in SARS-CoV-2 3CL(pro) detected in the SCORPIO-SR phase 3 trial.
    Antiviral Res. 2025 Jan 30:106097. doi: 10.1016/j.antiviral.2025.106097.
    PubMed     Abstract available
    
    
    
17. WU Q, Wu H, Hu Y, Zheng X, et al
    Immune evasion of Omicron variants JN.1, KP.2, and KP.3 to the polyclonal and monoclonal antibodies from COVID-19 convalescents and vaccine recipients.
    Antiviral Res. 2025 Jan 24:106092. doi: 10.1016/j.antiviral.2025.106092.
    PubMed     Abstract available
    
    
    
18. XU M, Zhang Z, Sun Y, Mai H, et al
    IgA class switching enhances neutralizing potency against SARS-CoV-2 by increased antibody hinge flexibility.
    Antiviral Res. 2025 Jan 17:106082. doi: 10.1016/j.antiviral.2025.106082.
    PubMed     Abstract available
    
    
    
19. MAIA AR, Gonzalez L, Bounab B, Grassi L, et al
    Intranasal exposure to commensal bacterium Rothia mucilaginosa protects against influenza A virus infection.
    Antiviral Res. 2025 Jan 2:106076. doi: 10.1016/j.antiviral.2025.106076.
    PubMed     Abstract available
    
    
    December 2024
20. GAO M, Zhang Z, Yao G, Zhang L, et al
    Design, synthesis, and biological evaluation of novel 2'-deoxy-2'-spirooxetane-7-deazapurine nucleoside analogs as anti-SARS-CoV-2 agents.
    Antiviral Res. 2024 Dec 30:106060. doi: 10.1016/j.antiviral.2024.106060.
    PubMed     Abstract available
    
    
    
21. MERCURI FA, Anderson GP, Miller BE, Demaison C, et al
    Discovery and development of INNA-051, a TLR2/6 agonist for the prevention of complications resulting from viral respiratory infections.
    Antiviral Res. 2024 Dec 27:106063. doi: 10.1016/j.antiviral.2024.106063.
    PubMed     Abstract available
    
    
    
22. SHANNON A, Canard B
    Nucleotide analogues and mpox: Repurposing the repurposable.
    Antiviral Res. 2024;234:106057.
    PubMed     Abstract available
    
    
    
23. WANG B, Xia H, Peng BH, Choi EJ, et al
    Pellino-1, a therapeutic target for control of SARS-CoV-2 infection and disease severity.
    Antiviral Res. 2024;233:106059.
    PubMed     Abstract available
    
    
    
24. SCHRELL L, Fuchs HL, Dickmanns A, Scheibner D, et al
    Inhibitors of dihydroorotate dehydrogenase synergize with the broad antiviral activity of 4'-fluorouridine.
    Antiviral Res. 2024 Dec 3:106046. doi: 10.1016/j.antiviral.2024.106046.
    PubMed     Abstract available
    
    
    
25. WELCH SR, Bilello JP, Carter K, Delang L, et al
    Meeting report of the 37th International Conference on Antiviral Research in Gold Coast, Australia, May 20-24, 2024, organized by the International Society for Antiviral Research.
    Antiviral Res. 2024;232:106037.
    PubMed     Abstract available
    
    
    November 2024
26. AMIN MR, Anwar KN, Ashraf MJ, Ghassemi M, et al
    Preventing human influenza and coronaviral mono or coinfection by blocking virus-induced sialylation.
    Antiviral Res. 2024;232:106041.
    PubMed     Abstract available
    
    
    
27. SRIWILAIJAROEN N, Hanamatsu H, Yokota I, Nishikaze T, et al
    Edible bird's nest: N- and O-glycan analysis and synergistic anti-avian influenza virus activity with neuraminidase inhibitors.
    Antiviral Res. 2024 Nov 20:106040. doi: 10.1016/j.antiviral.2024.106040.
    PubMed     Abstract available
    
    
    
28. MCGOVERN-GOOCH KR, Mani N, Gotchev D, Ardzinski A, et al
    Biological characterization of AB-343, a novel and potent SARS-CoV-2 M(pro) inhibitor with pan-coronavirus activity.
    Antiviral Res. 2024;232:106038.
    PubMed     Abstract available
    
    
    
29. SASAKI J, Sato A, Sasaki M, Okabe I, et al
    X-206 exhibits broad-spectrum anti-beta-coronavirus activity, covering SARS-CoV-2 variants and drug-resistant isolates.
    Antiviral Res. 2024 Nov 19:106039. doi: 10.1016/j.antiviral.2024.106039.
    PubMed     Abstract available
    
    
    
30. ZHANG W, Lin X, Li ZY, Zhang LJ, et al
    Novel intercellular spread mode of respiratory syncytial virus contributes to neutralization escape.
    Antiviral Res. 2024;231:106023.
    PubMed     Abstract available
    
    
    
31. ZHANG K, Yang XM, Sun H, Cheng ZS, et al
    Modulating apoptosis as a novel therapeutic strategy against Respiratory Syncytial Virus infection: insights from Rotenone.
    Antiviral Res. 2024;231:106007.
    PubMed     Abstract available
    
    
    
32. RICHTER M, Khrenova M, Kazakova E, Riabova O, et al
    Dynamic features of virus protein 1 and substitutions in the 3-phenyl ring determine the potency and broad-spectrum activity of capsid-binding pyrazolo[3,4-d]pyrimidines against rhinoviruses.
    Antiviral Res. 2024;231:105993.
    PubMed     Abstract available
    
    
    October 2024
33. NAKASHIMA M, Nobori H, Kuroda T, Shimba A, et al
    Oral 3CL protease inhibitor ensitrelvir suppressed SARS-CoV-2 shedding and infection in a hamster aerosol transmission model.
    Antiviral Res. 2024 Oct 28:106026. doi: 10.1016/j.antiviral.2024.106026.
    PubMed     Abstract available
    
    
    
34. LO CW, Kariv O, Hao C, Gammeltoft KA, et al
    Replication Capacity and Susceptibility of Nirmatrelvir-Resistant Mutants to Next-Generation Mpro Inhibitors in a SARS-CoV-2 Replicon System.
    Antiviral Res. 2024 Oct 16:106022. doi: 10.1016/j.antiviral.2024.106022.
    PubMed     Abstract available
    
    
    September 2024
35. VAN DER HORST D, Carter-Timofte ME, Danneels A, Silva da Costa L, et al
    Large-scale deep learning identifies the antiviral potential of PKI-179 and MTI-31 against coronaviruses.
    Antiviral Res. 2024;231:106012.
    PubMed     Abstract available
    
    
    
36. HERRMANN A, Gege C, Wangen C, Wagner S, et al
    Orally Bioavailable RORgamma/DHODH Dual Host-Targeting Small Molecules with Broad-Spectrum Antiviral Activity.
    Antiviral Res. 2024 Sep 19:106008. doi: 10.1016/j.antiviral.2024.106008.
    PubMed     Abstract available
    
    
    
37. KUMAR P, Zhang X, Shaha R, Kschischo M, et al
    Identification of antibody-resistant SARS-CoV-2 mutants via N4-Hydroxycytidine mutagenesis.
    Antiviral Res. 2024;231:106006.
    PubMed     Abstract available
    
    
    
38. DO TND, Abdelnabi R, Boda B, Constant S, et al
    The triple combination of Remdesivir (GS-441524), Molnupiravir and Ribavirin is highly efficient in inhibiting coronavirus replication in human nasal airway epithelial cell cultures and in a hamster infection model.
    Antiviral Res. 2024 Sep 3:105994. doi: 10.1016/j.antiviral.2024.105994.
    PubMed     Abstract available
    
    
    
39. BONNEUX B, Jacoby E, Ceconi M, Stobbelaar K, et al
    Direct-acting antivirals for RSV treatment, a review.
    Antiviral Res. 2024;229:105948.
    PubMed     Abstract available
    
    
    August 2024
40. YAMASAKI M, Saso W, Yamamoto T, Sato M, et al
    Anti-SARS-CoV-2 gapmer antisense oligonucleotides targeting the main protease region of viral RNA.
    Antiviral Res. 2024;230:105992.
    PubMed     Abstract available
    
    
    
41. LEE P, Kim J, Oh H, Kim CU, et al
    Coronavirus Nucleocapsid-based Vaccine Provides Partial Protection against Hetero-species Coronavirus in Murine Models.
    Antiviral Res. 2024 Aug 22:105991. doi: 10.1016/j.antiviral.2024.105991.
    PubMed     Abstract available
    
    
    
42. CONG Y, Dixit S, Perry DL, Huzella LM, et al
    Characterization of therapeutic antibodies efficacy against multiple SARS-CoV-2 variants in the hamster model.
    Antiviral Res. 2024 Aug 13:105987. doi: 10.1016/j.antiviral.2024.105987.
    PubMed     Abstract available
    
    
    
43. BONOMINI A, Zhang J, Ju H, Zago A, et al
    Synergistic activity of an RNA polymerase PA-PB1 interaction inhibitor with oseltamivir against human and avian influenza viruses in cell culture and in ovo.
    Antiviral Res. 2024 Aug 6:105980. doi: 10.1016/j.antiviral.2024.105980.
    PubMed     Abstract available
    
    
    
44. HAN Z, Mai Q, Zhao Y, Liu X, et al
    Mosaic neuraminidase-based vaccine induces antigen-specific T cell responses against homologous and heterologous influenza viruses.
    Antiviral Res. 2024 Aug 6:105978. doi: 10.1016/j.antiviral.2024.105978.
    PubMed     Abstract available
    
    
    
45. KEISER PT, Zhang W, Ricca M, Wacquiez A, et al
    Amidino-Rocaglates (ADRs), a class of synthetic rocaglates, are potent inhibitors of SARS-CoV-2 replication through inhibition of viral protein synthesis.
    Antiviral Res. 2024 Aug 6:105976. doi: 10.1016/j.antiviral.2024.105976.
    PubMed     Abstract available
    
    
    
46. YOON KW, Chu KB, Eom GD, Mao J, et al
    Orally Dissolving Film as a Potential Vaccine Delivery Carrier to Prevent Influenza Virus Infection.
    Antiviral Res. 2024 Aug 5:105979. doi: 10.1016/j.antiviral.2024.105979.
    PubMed     Abstract available
    
    
    July 2024
47. ROSALES R, McGovern BL, Rodriguez ML, Leiva-Rebollo R, et al
    Nirmatrelvir and Molnupiravir maintain potent in vitro and in vivo antiviral activity against circulating SARS-CoV-2 Omicron subvariants.
    Antiviral Res. 2024 Jul 25:105970. doi: 10.1016/j.antiviral.2024.105970.
    PubMed     Abstract available
    
    
    
48. OLIVEIRA EH, Monteleone-Cassiano AC, Tavares L, Santos JC, et al
    A mimetic peptide of ACE2 protects against SARS-CoV-2 infection and decreases pulmonary inflammation related to COVID-19.
    Antiviral Res. 2024;229:105968.
    PubMed     Abstract available
    
    
    
49. CHEN D, Su W, Choy KT, Chu YS, et al
    High throughput profiling identified PA-L106R amino acid substitution in A(H1N1)pdm09 influenza virus that confers reduced susceptibility to baloxavir in vitro.
    Antiviral Res. 2024 Jul 11:105961. doi: 10.1016/j.antiviral.2024.105961.
    PubMed     Abstract available
    
    
    
50. ANDREEV K, Jones JC, Seiler P, Kandeil A, et al
    Genotypic and phenotypic susceptibility of emerging avian influenza A viruses to neuraminidase and cap-dependent endonuclease inhibitors.
    Antiviral Res. 2024 Jul 8:105959. doi: 10.1016/j.antiviral.2024.105959.
    PubMed     Abstract available
    
    
    
51. XU Y, Sun F, Chuai Z, Wang J, et al
    Cold-adapted influenza vaccine carrying three repeats of a respiratory syncytial virus (RSV) fusion glycoprotein epitope site protects BALB/c mice and cotton rats against RSV infection.
    Antiviral Res. 2024 Jul 8:105960. doi: 10.1016/j.antiviral.2024.105960.
    PubMed     Abstract available
    
    
    
52. YOTSUYANAGI H, Ohmagari N, Doi Y, Yamato M, et al
    Prevention of Post COVID-19 Condition by Early Treatment with Ensitrelvir in the Phase 3 SCORPIO-SR Trial.
    Antiviral Res. 2024 Jul 5:105958. doi: 10.1016/j.antiviral.2024.105958.
    PubMed     Abstract available
    
    
    
53. CHON I, Wagatsuma K, Saito R, Tang JW, et al
    Detection of influenza A(H3N2) viruses with polymerase acidic subunit substitutions after and prior to baloxavir marboxil treatment during the 2022-2023 influenza season in Japan.
    Antiviral Res. 2024 Jul 3:105956. doi: 10.1016/j.antiviral.2024.105956.
    PubMed     Abstract available
    
    
    
54. JI J, Tang T, Zhu M, Wu Z, et al
    Boosting the immune response in COVID-19 vaccines via an Alum:CpG complex adjuvant.
    Antiviral Res. 2024 Jul 2:105954. doi: 10.1016/j.antiviral.2024.105954.
    PubMed     Abstract available
    
    
    
55. BONNEUX B, Shareef A, Tcherniuk S, Anson B, et al
    JNJ-7184, a respiratory syncytial virus inhibitor targeting the connector domain of the viral polymerase.
    Antiviral Res. 2024;227:105907.
    PubMed     Abstract available
    
    
    June 2024
56. WILLIAMS N, Silva F, Schmolke M
    Harnessing host enhancers of SARS-CoV-2 entry as novel targets for antiviral therapy.
    Antiviral Res. 2024 Jun 28:105951. doi: 10.1016/j.antiviral.2024.105951.
    PubMed     Abstract available
    
    
    
57. LV L, Yang X, Zhang Y, Ren X, et al
    hnRNPAB inhibits Influenza A virus infection by disturbing polymerase activity.
    Antiviral Res. 2024;228:105925.
    PubMed     Abstract available
    
    
    
58. DANIELS A, Padariya M, Fletcher S, Ball K, et al
    Molecules targeting a novel homotrimer cavity of Spike protein attenuate replication of SARS-CoV-2.
    Antiviral Res. 2024;228:105949.
    PubMed     Abstract available
    
    
    
59. BALIGA-GIL A, Soszynska-Jozwiak M, Ruszkowska A, Szczesniak I, et al
    Targeting sgRNA N secondary structure as a way of inhibiting SARS-CoV-2 replication.
    Antiviral Res. 2024 Jun 24:105946. doi: 10.1016/j.antiviral.2024.105946.
    PubMed     Abstract available
    
    
    
60. LIU X, Zheng M, Zhang H, Feng B, et al
    Characterization and noncovalent inhibition of the K63-deubiquitinase activity of SARS-CoV-2 PLpro.
    Antiviral Res. 2024 Jun 22:105944. doi: 10.1016/j.antiviral.2024.105944.
    PubMed     Abstract available
    
    
    
61. DICKEY TH, Salinas ND, Patel P, Orr-Gonzalez S, et al
    RBD design increases the functional antibody titers elicited by SARS-CoV-2 spike vaccination.
    Antiviral Res. 2024 Jun 18:105937. doi: 10.1016/j.antiviral.2024.105937.
    PubMed     Abstract available
    
    
    
62. SUN Y, Wagatsuma K, Saito R, Sato I, et al
    Duration of fever in children infected with influenza A(H1N1)pdm09, A(H3N2) or B virus and treated with baloxavir marboxil, oseltamivir, laninamivir, or zanamivir in Japan during the 2012-2013 and 2019-2020 influenza seasons.
    Antiviral Res. 2024 Jun 17:105938. doi: 10.1016/j.antiviral.2024.105938.
    PubMed     Abstract available
    
    
    
63. ZHAI G, Fu W, Yuan S, Sun P, et al
    A fusion protein approach to integrate antiviral and anti-inflammatory activities for developing new therapeutics against influenza A virus infection.
    Antiviral Res. 2024 Jun 9:105924. doi: 10.1016/j.antiviral.2024.105924.
    PubMed     Abstract available
    
    
    
64. LI J, Cui H, Yao Y, Niu J, et al
    Anti-influenza activity of CPAVM1 protease secreted by Bacillus subtilis LjM2.
    Antiviral Res. 2024 Jun 6:105919. doi: 10.1016/j.antiviral.2024.105919.
    PubMed     Abstract available
    
    
    
65. GUO M, Peng J, Guo P, Wang Q, et al
    Inhalation of 2, 4-di-tert-butylphenol-Loaded micelles suppresses respiratory syncytial virus infection in mice.
    Antiviral Res. 2024;226:105880.
    PubMed     Abstract available
    
    
    May 2024
66. VAN LOY B, Stevaert A, Naesens L
    The coronavirus nsp15 endoribonuclease: a puzzling protein and pertinent antiviral drug target.
    Antiviral Res. 2024 May 31:105921. doi: 10.1016/j.antiviral.2024.105921.
    PubMed     Abstract available
    
    
    
67. LE UNP, Chang YJ, Lu CH, Chen Y, et al
    Glycyrrhizic acid conjugates with amino acid methyl esters target the main protease, exhibiting antiviral activity against wild-type and nirmatrelvir-resistant SARS-CoV-2 variants.
    Antiviral Res. 2024;227:105920.
    PubMed     Abstract available
    
    
    
68. FRANCO-MAY DA, Gomez-Carballo J, Barrera-Badillo G, Cruz-Ortiz MN, et al
    Low antiviral resistance in Influenza A and B viruses isolated in Mexico from 2010 to 2023.
    Antiviral Res. 2024;227:105918.
    PubMed     Abstract available
    
    
    
69. LIANG Y, Xiao W, Peng Y, Zhang S, et al
    Development of Nanoparticle Vaccines Utilizing Designed Fc-Binding Homo-oligomers and RBD-Fc of SARS-CoV-2.
    Antiviral Res. 2024 May 21:105917. doi: 10.1016/j.antiviral.2024.105917.
    PubMed     Abstract available
    
    
    
70. HUANG J, Wang W, Li H, Bai Y, et al
    Three in one: An effective and universal vaccine expressing heterologous tandem RBD trimer by rabies virus vector protects mice against SARS-CoV-2.
    Antiviral Res. 2024;227:105905.
    PubMed     Abstract available
    
    
    
71. PANDEY K, Acharya A, Pal D, Jain P, et al
    SRX3177, a CDK4/6-PI3K-BET inhibitor, in combination with an RdRp inhibitor, Molnupiravir, or an entry inhibitor MU-UNMC-2, has potent antiviral activity against the Omicron variant of SARS-CoV-2.
    Antiviral Res. 2024;227:105904.
    PubMed     Abstract available
    
    
    
72. SALGADO-BENVINDO C, Tas A, Zevenhoven-Dobbe JC, van der Meer Y, et al
    Characterization of SARS-CoV-2 replication in human H1299/ACE2 cells: a versatile and practical infection model for antiviral research and beyond.
    Antiviral Res. 2024 May 7:105903. doi: 10.1016/j.antiviral.2024.105903.
    PubMed     Abstract available
    
    
    April 2024
73. LIU X, Wang Y, Sun L, Xiao G, et al
    Screening and optimization of shark nanobodies against SARS-CoV-2 Spike RBD.
    Antiviral Res. 2024 Apr 29:105898. doi: 10.1016/j.antiviral.2024.105898.
    PubMed     Abstract available
    
    
    
74. ARDUINO I, Francese R, Civra A, Feyles E, et al
    Polyoxometalate exerts broad-spectrum activity against human respiratory viruses hampering viral entry.
    Antiviral Res. 2024;226:105897.
    PubMed     Abstract available
    
    
    
75. AMERATUNGA R, Jordan A, Lehnert K, Leung E, et al
    SARS-CoV-2 evolution has increased resistance to monoclonal antibodies and first-generation COVID-19 vaccines: Is there a future therapeutic role for soluble ACE2 receptors for COVID-19?
    Antiviral Res. 2024 Apr 25:105894. doi: 10.1016/j.antiviral.2024.105894.
    PubMed     Abstract available
    
    
    
76. GLITSCHER M, Benz NI, Sabino C, Murra RO, et al
    Inhibition of Pim kinases triggers a broad antiviral activity by affecting innate immunity and via the PI3K-Akt-mTOR axis the endolysosomal system.
    Antiviral Res. 2024;226:105891.
    PubMed     Abstract available
    
    
    
77. TOLKSDORF B, Heinze J, Niemeyer D, Rohrs V, et al
    Development of a highly stable, active small interfering RNA with broad activity against SARS-CoV viruses.
    Antiviral Res. 2024 Apr 8:105879. doi: 10.1016/j.antiviral.2024.105879.
    PubMed     Abstract available
    
    
    March 2024
78. RAHA JR, Kim KH, Bhatnagar N, Liu R, et al
    Supplementation of seasonal vaccine with multi-subtype neuraminidase and M2 ectodomain virus-like particle improves protection against homologous and heterologous influenza viruses in aged mice.
    Antiviral Res. 2024;225:105877.
    PubMed     Abstract available
    
    
    
79. KHATUA K, Alugubelli YR, Yang KS, Vulupala VR, et al
    Azapeptides with unique covalent warheads as SARS-CoV-2 main protease inhibitors.
    Antiviral Res. 2024;225:105874.
    PubMed     Abstract available
    
    
    
80. SINIAVIN AE, Gushchin VA, Shastina NS, Darnotuk ES, et al
    New conjugates based on N4-hydroxycytidine with more potent antiviral efficacy in vitro than EIDD-2801 against SARS-CoV-2 and other human coronaviruses.
    Antiviral Res. 2024 Mar 28:105871. doi: 10.1016/j.antiviral.2024.105871.
    PubMed     Abstract available
    
    
    
81. PEREZ-VARGAS J, Lemieux G, Thompson CAH, Desilets A, et al
    Nanomolar anti-SARS-CoV-2 Omicron activity of the host-directed TMPRSS2 inhibitor N-0385 and synergistic action with direct-acting antivirals.
    Antiviral Res. 2024 Mar 26:105869. doi: 10.1016/j.antiviral.2024.105869.
    PubMed     Abstract available
    
    
    
82. MOON C, Porges E, Roberts A, Bacon J, et al
    A combination of nirmatrelvir and ombitasvir boosts inhibition of SARS-CoV-2 replication.
    Antiviral Res. 2024 Mar 14:105859. doi: 10.1016/j.antiviral.2024.105859.
    PubMed     Abstract available
    
    
    
83. BANDYSZEWSKA M, Ambrozek-Latecka M, Hoser G, Grzanka M, et al
    SARS-CoV-2 virus-like particle variants alpha and delta mimic the native viruses in their differential inflammasome activating potential.
    Antiviral Res. 2024 Mar 5:105857. doi: 10.1016/j.antiviral.2024.105857.
    PubMed     Abstract available
    
    
    
84. WANG W, Wang S, Meng X, Zhao Y, et al
    A virus-like particle candidate vaccine based on CRISPR/Cas9 gene editing technology elicits broad-spectrum protection against SARS-CoV-2.
    Antiviral Res. 2024 Mar 4:105854. doi: 10.1016/j.antiviral.2024.105854.
    PubMed     Abstract available
    
    
    
85. KLEVANSKI M, Kim H, Heilemann M, Kuner T, et al
    Glycan-directed SARS-CoV-2 inhibition by leek extract and lectins with insights into the mode-of-action of Concanavalin A.
    Antiviral Res. 2024 Mar 4:105856. doi: 10.1016/j.antiviral.2024.105856.
    PubMed     Abstract available
    
    
    
86. SCHREIBER A, Rodner F, Oberberg N, Anhlan D, et al
    The host-targeted antiviral drug Zapnometinib exhibits a high barrier to the development of SARS-CoV-2 resistance.
    Antiviral Res. 2024 Mar 2:105840. doi: 10.1016/j.antiviral.2024.105840.
    PubMed     Abstract available
    
    
    February 2024
87. GOTO T, Kawai N, Bando T, Takasaki Y, et al
    Virological and clinical outcomes in outpatients treated with baloxavir or neuraminidase inhibitors for A(H3N2) influenza: A multicenter study of the 2022-2023 season.
    Antiviral Res. 2024;224:105853.
    PubMed     Abstract available
    
    
    
88. NOBORI H, Baba K, Kuroda T, Baba K, et al
    Prophylactic effect of ensitrelvir in mice infected with SARS-CoV-2.
    Antiviral Res. 2024;224:105852.
    PubMed     Abstract available
    
    
    
89. LI H, Sun M, Lei F, Liu J, et al
    Methyl rosmarinate is an allosteric inhibitor of SARS-cov-2 3?C?L protease as a potential candidate against SARS-cov-2 infection.
    Antiviral Res. 2024 Feb 24:105841. doi: 10.1016/j.antiviral.2024.105841.
    PubMed     Abstract available
    
    
    
90. BIGOTTI MG, Klein K, Gan ES, Anastasina M, et al
    The alpha-dystroglycan N-terminus is a broad-spectrum antiviral agent against SARS-CoV-2 and enveloped viruses.
    Antiviral Res. 2024 Feb 20:105837. doi: 10.1016/j.antiviral.2024.105837.
    PubMed     Abstract available
    
    
    
91. ZHANG X, Xia Y, Li P, Wu Z, et al
    Discovery of cyperenoic acid as a potent and novel entry inhibitor of influenza A virus.
    Antiviral Res. 2024 Feb 11:105822. doi: 10.1016/j.antiviral.2024.105822.
    PubMed     Abstract available
    
    
    
92. SINHA D, Yaugel-Novoa M, Waeckel L, Paul S, et al
    Unmasking the potential of secretory IgA and its pivotal role in protection from respiratory viruses.
    Antiviral Res. 2024 Feb 6:105823. doi: 10.1016/j.antiviral.2024.105823.
    PubMed     Abstract available
    
    
    
93. IZMAILYAN R, Matevosyan M, Khachatryan H, Shavina A, et al
    Discovery of new antiviral agents through artificial intelligence: In vitro and in vivo results.
    Antiviral Res. 2024;222:105818.
    PubMed     Abstract available
    
    
    
94. RICHTER M, Doring K, Blaas D, Riabova O, et al
    Molecular mechanism of rhinovirus escape from the Pyrazolo[3,4-d]pyrimidine capsid-binding inhibitor OBR-5-340 via mutations distant from the binding pocket: Derivatives that brake resistance.
    Antiviral Res. 2024;222:105810.
    PubMed     Abstract available
    
    
    
95. LOAIZA RA, Ramirez RA, Sepulveda-Alfaro J, Ramirez MA, et al
    A molecular perspective for the development of antibodies against the human respiratory syncytial virus.
    Antiviral Res. 2024;222:105783.
    PubMed     Abstract available
    
    
    January 2024
96. WINIGER RR, Perez L
    Therapeutic antibodies and alternative formats against SARS-CoV-2.
    Antiviral Res. 2024 Jan 31:105820. doi: 10.1016/j.antiviral.2024.105820.
    PubMed     Abstract available
    
    
    
97. BOUZIDI HS, Driouich JS, Klitting R, Bernadin O, et al
    Generation and evaluation of protease inhibitor-resistant SARS-CoV-2 strains.
    Antiviral Res. 2024 Jan 23:105814. doi: 10.1016/j.antiviral.2024.105814.
    PubMed     Abstract available
    
    
    
98. BOGACHEVA MS, Kuivanen S, Potdar S, Hassinen A, et al
    Drug repurposing platform for deciphering the druggable SARS-CoV-2 interactome.
    Antiviral Res. 2024 Jan 23:105813. doi: 10.1016/j.antiviral.2024.105813.
    PubMed     Abstract available
    
    
    
99. IDRIS A, Supramaniam A, Tayyar Y, Kelly G, et al
    An intranasally delivered ultra-conserved siRNA prophylactically represses SARS-CoV-2 infection in the lung and nasal cavity.
    Antiviral Res. 2024;222:105815.
    PubMed     Abstract available
    
    
    
100. MATTHYS A, Saelens X
     Promises and challenges of single-domain antibodies to control influenza.
     Antiviral Res. 2024 Jan 12:105807. doi: 10.1016/j.antiviral.2024.105807.
     PubMed     Abstract available
     
     
     
101. GOVEDNIK T, Lainscek D, Kuhar U, Lachish M, et al
     TXM peptides inhibit SARS-CoV-2 infection, syncytia formation, and lower inflammatory consequences.
     Antiviral Res. 2024 Jan 9:105806. doi: 10.1016/j.antiviral.2024.105806.
     PubMed     Abstract available
     
     
     
102. ZOU G, Cao S, Gao Z, Yie J, et al
     Current state and challenges in respiratory syncytial virus drug discovery and development.
     Antiviral Res. 2024;221:105791.
     PubMed     Abstract available
     
     
     December 2023
103. CHEN X, Tian L, Zhang L, Gao W, et al
     Deubiquitinase USP39 promotes SARS-CoV-2 replication by deubiquitinating and stabilizing the envelope protein.
     Antiviral Res. 2023;221:105790.
     PubMed     Abstract available
     
     
     
104. SUN X, Ma H, Wang X, Bao Z, et al
     Broadly neutralizing antibodies to combat influenza virus infection.
     Antiviral Res. 2023 Dec 23:105785. doi: 10.1016/j.antiviral.2023.105785.
     PubMed     Abstract available
     
     
     
105. AKSU M, Kumar P, Guttler T, Taxer W, et al
     Nanobodies to multiple spike variants and inhalation of nanobody-containing aerosols neutralize SARS-CoV-2 in cell culture and hamsters.
     Antiviral Res. 2023 Dec 6:105778. doi: 10.1016/j.antiviral.2023.105778.
     PubMed     Abstract available
     
     
     
106. ZUR M, Peselev T, Yanko S, Rotshild V, et al
     Efficacy and safety of antiviral treatments for symptomatic COVID-19 outpatients: Systematic review and network meta-analysis.
     Antiviral Res. 2023 Dec 4:105768. doi: 10.1016/j.antiviral.2023.105768.
     PubMed     Abstract available
     
     
     November 2023
107. WANG S, Cui H, Zhang C, Li W, et al
     Oral delivery of a chitosan adjuvanted COVID-19 vaccine provides long-lasting and broad-spectrum protection against SARS-CoV-2 variants of concern in golden hamsters.
     Antiviral Res. 2023 Nov 28:105765. doi: 10.1016/j.antiviral.2023.105765.
     PubMed     Abstract available
     
     
     
108. GOMEZ-CARBALLA A, Albericio G, Montoto-Louzao J, Perez P, et al
     Lung transcriptomics of K18-hACE2 mice highlights mechanisms and genes involved in the MVA-S vaccine-mediated immune response and protection against SARS-CoV-2 infection.
     Antiviral Res. 2023 Nov 20:105760. doi: 10.1016/j.antiviral.2023.105760.
     PubMed     Abstract available
     
     
     
109. WU CY, Tseng YC, Kao SE, Wu LY, et al
     Monoglycosylated SARS-CoV-2 receptor binding domain fused with HA(stem)-scaffolded protein vaccine confers broad protective immunity against SARS-CoV-2 and influenza viruses.
     Antiviral Res. 2023 Nov 18:105759. doi: 10.1016/j.antiviral.2023.105759.
     PubMed     Abstract available
     
     
     
110. ZHANG QY, Zhang HQ, Zhang YN, Zhang ZR, et al
     Newcastle Disease Virus (NDV)-based vaccine candidate against SARS-CoV-2 Omicron by intranasal immunization.
     Antiviral Res. 2023 Nov 18:105757. doi: 10.1016/j.antiviral.2023.105757.
     PubMed     Abstract available
     
     
     
111. SADHU S, Dandotiya J, Dalal R, Khatri R, et al
     Fangchinoline inhibits SARS-CoV-2 and MERS-CoV entry.
     Antiviral Res. 2023 Nov 8:105743. doi: 10.1016/j.antiviral.2023.105743.
     PubMed     Abstract available
     
     
     
112. HSIEH HC, Chen CC, Chou PH, Liu WC, et al
     Induction of neutralizing antibodies and mucosal IgA through intranasal immunization with the receptor binding domain of SARS-CoV-2 spike protein fused with the type IIb E. coli heat-labile enterotoxin A subunit.
     Antiviral Res. 2023 Nov 8:105752. doi: 10.1016/j.antiviral.2023.105752.
     PubMed     Abstract available
     
     
     
113. SU WC, Chen ZY, Chang YS, Jeng KS, et al
     Functional assessments of SARS-CoV-2 single-round infectious particles with variant-specific spike proteins on infectivity, drug sensitivity, and antibody neutralization.
     Antiviral Res. 2023 Nov 7:105744. doi: 10.1016/j.antiviral.2023.105744.
     PubMed     Abstract available
     
     
     
114. KIM DG, Kim U, Park IH, Ryu B, et al
     A bivalent form of a RBD-specific synthetic antibody effectively neutralizes SARS-CoV-2 variants.
     Antiviral Res. 2023 Nov 7:105738. doi: 10.1016/j.antiviral.2023.105738.
     PubMed     Abstract available
     
     
     
115. LUGANINI A, Sibille G, Pavan M, Mello Grand M, et al
     Mechanisms of antiviral activity of the new hDHODH inhibitor MEDS433 against respiratory syncytial virus replication.
     Antiviral Res. 2023;219:105734.
     PubMed     Abstract available
     
     
     October 2023
116. DEMIAN WL, Jacob RA, Cormier O, Nazli A, et al
     ASK1 inhibitors are potential pan-antiviral drugs, which dampen replication of diverse viruses including SARS-CoV2.
     Antiviral Res. 2023 Oct 18:105736. doi: 10.1016/j.antiviral.2023.105736.
     PubMed     Abstract available
     
     
     
117. PALLA SR, Li CW, Chao TL, Lo HV, et al
     Synthesis, evaluation, and mechanism of 1-(4-(arylethylenylcarbonyl)phenyl)-4-carboxy-2-pyrrolidinones as potent reversible SARS-CoV-2 entry inhibitors.
     Antiviral Res. 2023 Oct 17:105735. doi: 10.1016/j.antiviral.2023.105735.
     PubMed     Abstract available
     
     
     
118. KONKEL R, Milewska A, Do NDT, Barreto Duran E, et al
     Anti-SARS-CoV-2 activity of cyanopeptolins produced by Nostoc edaphicum CCNP1411.
     Antiviral Res. 2023 Oct 12:105731. doi: 10.1016/j.antiviral.2023.105731.
     PubMed     Abstract available
     
     
     September 2023
119. GAO R, Pascua PNQ, Nguyen HT, Chesnokov A, et al
     New insights into the neuraminidase-mediated hemagglutination activity of influenza A(H3N2) viruses.
     Antiviral Res. 2023;218:105719.
     PubMed     Abstract available
     
     
     
120. BENNETT RP, Yoluc Y, Salter JD, Ripp A, et al
     Sangivamycin is preferentially incorporated into viral RNA by the SARS-CoV-2 polymerase.
     Antiviral Res. 2023 Sep 8:105716. doi: 10.1016/j.antiviral.2023.105716.
     PubMed     Abstract available
     
     
     August 2023
121. IVASHCHENKO AA, Jones JC, Shkil DO, Ivanenkov YA, et al
     Resistance profiles for the investigational neuraminidase inhibitor AV5080 in influenza A and B viruses.
     Antiviral Res. 2023;217:105701.
     PubMed     Abstract available
     
     
     
122. VANDERLINDEN E, Boonen A, Noppen S, Schoofs G, et al
     PRO-2000 exhibits SARS-CoV-2 antiviral activity by interfering with spike-heparin binding.
     Antiviral Res. 2023;217:105700.
     PubMed     Abstract available
     
     
     
123. CORONA A, Madia VN, De Santis R, Manelfi C, et al
     Diketo acid inhibitors of nsp13 of SARS-CoV-2 block viral replication.
     Antiviral Res. 2023;217:105697.
     PubMed     Abstract available
     
     
     July 2023
124. NGUYEN HT, Chesnokov A, De La Cruz J, Pascua PNQ, et al
     Antiviral susceptibility of clade 2.3.4.4b highly pathogenic avian influenza A(H5N1) viruses isolated from birds and mammals in the United States, 2022.
     Antiviral Res. 2023 Jul 24:105679. doi: 10.1016/j.antiviral.2023.105679.
     PubMed     Abstract available
     
     
     
125. SPENGLER JR, Carter K, Delang L, Durantel D, et al
     Meeting report: 36th international conference on antiviral research in Lyon, France, March 13-17, 2023.
     Antiviral Res. 2023 Jul 24:105678. doi: 10.1016/j.antiviral.2023.105678.
     PubMed     Abstract available
     
     
     
126. SUPREWICZ L, Szczepanski A, Lenart M, Piktel E, et al
     Ceragenins exhibit antiviral activity against SARS-CoV-2 by increasing the expression and release of type I interferons upon activation of the host's immune response.
     Antiviral Res. 2023 Jul 20:105676. doi: 10.1016/j.antiviral.2023.105676.
     PubMed     Abstract available
     
     
     
127. BOWDEN-REID E, Ledger S, Zhang Y, Di Giallonardo F, et al
     Novel siRNA therapeutics demonstrate multi-variant efficacy against SARS-CoV-2.
     Antiviral Res. 2023 Jul 19:105677. doi: 10.1016/j.antiviral.2023.105677.
     PubMed     Abstract available
     
     
     
128. TAKASHITA E, Fujisaki S, Morita H, Nagata S, et al
     Assessment of the frequency of SARS-CoV-2 Omicron variant escape from RNA-dependent RNA polymerase inhibitors and 3C-like protease inhibitors.
     Antiviral Res. 2023;216:105671.
     PubMed     Abstract available
     
     
     
129. JEONG JH, Choi JH, Kim BK, Min SC, et al
     Evaluating Z-FA-FMK, a host cathepsin L protease inhibitor, as a potent and broad-spectrum antiviral therapy against SARS-CoV-2 and related coronaviruses.
     Antiviral Res. 2023 Jul 10:105669. doi: 10.1016/j.antiviral.2023.105669.
     PubMed     Abstract available
     
     
     
130. FENG Y, Yang Y, Zou S, Qiu S, et al
     Identification of alpha-linolenic acid as a broad-spectrum antiviral against zika, dengue, herpes simplex, influenza virus and SARS-CoV-2 infection.
     Antiviral Res. 2023 Jul 8:105666. doi: 10.1016/j.antiviral.2023.105666.
     PubMed     Abstract available
     
     
     June 2023
131. MU S, Zou X, Wang Y, Deng X, et al
     The combined effect of oseltamivir and favipiravir on influenza a virus evolution in patients hospitalized with severe influenza.
     Antiviral Res. 2023 Jun 25:105657. doi: 10.1016/j.antiviral.2023.105657.
     PubMed     Abstract available
     
     
     
132. CAI H, Yan J, Liu S, Li P, et al
     Paxlovid for hospitalized COVID-19 patients with chronic kidney disease.
     Antiviral Res. 2023 Jun 25:105659. doi: 10.1016/j.antiviral.2023.105659.
     PubMed     Abstract available
     
     
     
133. MILAN BONOTTO R, Mitrovic A, Sosic I, Martinez-Orellana P, et al
     Cathepsin inhibitors nitroxoline and its derivatives inhibit SARS-CoV-2 infection.
     Antiviral Res. 2023;216:105655.
     PubMed     Abstract available
     
     
     
134. JUNG HE, Ku KB, Kang BH, Park JH, et al
     Intranasal delivery of an adenovirus-vector vaccine co-expressing a modified spike protein and a genetic adjuvant confers lasting mucosal immunity against SARS-CoV-2.
     Antiviral Res. 2023;216:105656.
     PubMed     Abstract available
     
     
     
135. CHANG YJ, Le UNP, Liu JJ, Li SR, et al
     Combining virtual screening with cis-/trans-cleavage enzymatic assays effectively reveals broad-spectrum inhibitors that target the main proteases of SARS-CoV-2 and MERS-CoV.
     Antiviral Res. 2023 Jun 13:105653. doi: 10.1016/j.antiviral.2023.105653.
     PubMed     Abstract available
     
     
     
136. ZHANG J, Nian X, Liu B, Zhang Z, et al
     Development of MDCK-based quadrivalent split seasonal influenza virus vaccine with high safety and immunoprotection: A preclinical study.
     Antiviral Res. 2023;216:105639.
     PubMed     Abstract available
     
     
     May 2023
137. WU CY, Kao SE, Tseng YC, Lin YP, et al
     Pilot-scale production of inactivated monoglycosylated split H(1)N(1) influenza virus vaccine provides cross-strain protection against influenza viruses.
     Antiviral Res. 2023 May 30:105640. doi: 10.1016/j.antiviral.2023.105640.
     PubMed     Abstract available
     
     
     
138. WANG X, Lin L, Chen Z, Si W, et al
     Mutations at site 207 of influenza a virus NS1 protein switch its function in regulating RIG-I-like receptors mediated antiviral responses.
     Antiviral Res. 2023 May 23:105641. doi: 10.1016/j.antiviral.2023.105641.
     PubMed     Abstract available
     
     
     
139. DRIOUICH JS, Bernadin O, Touret F, de Lamballerie X, et al
     Activity of Sotrovimab against BQ.1.1 and XBB.1 Omicron sublineages in a hamster model.
     Antiviral Res. 2023 May 17:105638. doi: 10.1016/j.antiviral.2023.105638.
     PubMed     Abstract available
     
     
     
140. HUANG X, Fan W, Sun J, Yang J, et al
     SARS-CoV-2 induces cardiomyocyte apoptosis and inflammation but can be ameliorated by ACE inhibitor Captopril.
     Antiviral Res. 2023 May 17:105636. doi: 10.1016/j.antiviral.2023.105636.
     PubMed     Abstract available
     
     
     
141. HU J, Zhang L, Zheng X, Wang G, et al
     Long noncoding RNA #61 exerts a broad anti-influenza a virus effect by its long arm rings.
     Antiviral Res. 2023 May 15:105637. doi: 10.1016/j.antiviral.2023.105637.
     PubMed     Abstract available
     
     
     
142. YANG X, Long F, Jia W, Zhang M, et al
     Artesunate inhibits PDE4 leading to intracellular cAMP accumulation, reduced ERK/MAPK signaling, and blockade of influenza A virus vRNP nuclear export.
     Antiviral Res. 2023 May 14:105635. doi: 10.1016/j.antiviral.2023.105635.
     PubMed     Abstract available
     
     
     April 2023
143. CHO J, Shin Y, Yang JS, Kim JW, et al
     Evaluation of antiviral drugs against newly emerged SARS-CoV-2 Omicron subvariants.
     Antiviral Res. 2023;214:105609.
     PubMed     Abstract available
     
     
     
144. LI Y, Wang K, Sun H, Wu S, et al
     Omicsynin B4 potently blocks coronavirus infection by inhibiting host proteases cathepsin L and TMPRSS2.
     Antiviral Res. 2023 Apr 17:105606. doi: 10.1016/j.antiviral.2023.105606.
     PubMed     Abstract available
     
     
     
145. CONG Y, Lee JH, Perry DL, Cooper K, et al
     Longitudinal analyses using (18)F-Fluorodeoxyglucose positron emission tomography with computed tomography as a measure of COVID-19 severity in the aged, young, and humanized ACE2 SARS-CoV-2 hamster models.
     Antiviral Res. 2023 Apr 15:105605. doi: 10.1016/j.antiviral.2023.105605.
     PubMed     Abstract available
     
     
     March 2023
146. SON S, Ahn SB, Kim G, Jang Y, et al
     Identification of broad-spectrum neutralizing antibodies against influenza A virus and evaluation of their prophylactic efficacy in mice.
     Antiviral Res. 2023;213:105591.
     PubMed     Abstract available
     
     
     
147. BILLS C, Xie X, Shi PY
     The multiple roles of nsp6 in the molecular pathogenesis of SARS-CoV-2.
     Antiviral Res. 2023;213:105590.
     PubMed     Abstract available
     
     
     
148. CONG Y, Mucker EM, Perry DL, Dixit S, et al
     Evaluation of a panel of therapeutic antibody clinical candidates for efficacy against SARS-CoV-2 in Syrian hamsters.
     Antiviral Res. 2023;213:105589.
     PubMed     Abstract available
     
     
     
149. YANG Y, Cao L, Yan M, Zhou J, et al
     Synthesis of deuterated S-217622 (Ensitrelvir) with antiviral activity against coronaviruses including SARS-CoV-2.
     Antiviral Res. 2023 Mar 28:105586. doi: 10.1016/j.antiviral.2023.105586.
     PubMed     Abstract available
     
     
     
150. VANHULLE E, Doijen J, Stroobants J, Provinciael B, et al
     Cellular electrical impedance to profile SARS-CoV-2 fusion inhibitors and to assess the fusogenic potential of spike mutants.
     Antiviral Res. 2023;213:105587.
     PubMed     Abstract available
     
     
     
151. DICHTL S, Diem G, Jager M, Zaderer V, et al
     Antiviral drugs block replication of highly immune-evasive Omicron subvariants ex vivo, but fail to reduce tissue inflammation.
     Antiviral Res. 2023 Mar 23:105581. doi: 10.1016/j.antiviral.2023.105581.
     PubMed     Abstract available
     
     
     
152. ALVES RPDS, Wang YT, Mikulski Z, McArdle S, et al
     SARS-CoV-2 Omicron (B.1.1.529) shows minimal neurotropism in a double-humanized mouse model.
     Antiviral Res. 2023 Mar 18:105580. doi: 10.1016/j.antiviral.2023.105580.
     PubMed     Abstract available
     
     
     
153. LU C, Zhang Y, Liu X, Hou F, et al
     Heterologous boost with mRNA vaccines against SARS-CoV-2 Delta/Omicron variants following an inactivated whole-virus vaccine.
     Antiviral Res. 2023;212:105556.
     PubMed     Abstract available
     
     
     
154. KIM JW, Heo K, Kim HJ, Yoo Y, et al
     Novel bispecific human antibody platform specifically targeting a fully open spike conformation potently neutralizes multiple SARS-CoV-2 variants.
     Antiviral Res. 2023;212:105576.
     PubMed     Abstract available
     
     
     
155. SHEKUNOV EV, Zlodeeva PD, Efimova SS, Muryleva AA, et al
     Cyclic lipopeptides as membrane fusion inhibitors against SARS-CoV-2: New tricks for old dogs.
     Antiviral Res. 2023;212:105575.
     PubMed     Abstract available
     
     
     
156. ISSMAIL L, Ramsbeck D, Jager C, Henning T, et al
     Identification and evaluation of a novel tribenzamide derivative as an inhibitor targeting the entry of the respiratory syncytial virus.
     Antiviral Res. 2023;211:105547.
     PubMed     Abstract available
     
     
     
157. HU Y, Zhu Y, Yu Y, Liu N, et al
     Design and characterization of novel SARS-CoV-2 fusion inhibitors with N-terminally extended HR2 peptides.
     Antiviral Res. 2023;212:105571.
     PubMed     Abstract available
     
     
     February 2023
158. XIAO Y, Yan Y, Chang L, Ji H, et al
     CDK4/6 inhibitor palbociclib promotes SARS-CoV-2 cell entry by down-regulating SKP2 dependent ACE2 degradation.
     Antiviral Res. 2023 Feb 18:105558. doi: 10.1016/j.antiviral.2023.105558.
     PubMed     Abstract available
     
     
     
159. LI J, Wang Y, Solanki K, Atre R, et al
     Nirmatrelvir exerts distinct antiviral potency against different human coronaviruses.
     Antiviral Res. 2023 Feb 13:105555. doi: 10.1016/j.antiviral.2023.105555.
     PubMed     Abstract available
     
     
     
160. MERINO VF, Yan Y, Ordonez AA, Bullen CK, et al
     Nucleolin mediates SARS-CoV-2 replication and viral-induced apoptosis of host cells.
     Antiviral Res. 2023;211:105550.
     PubMed     Abstract available
     
     
     January 2023
161. ZHU Y, Li M, Liu N, Wu T, et al
     Development of highly effective LCB1-based lipopeptides targeting the spike receptor-binding motif of SARS-CoV-2.
     Antiviral Res. 2023;211:105541.
     PubMed     Abstract available
     
     
     
162. BASILE A, Zannella C, De Marco M, Sanna G, et al
     Spike-mediated viral membrane fusion is inhibited by a specific anti-IFITM2 monoclonal antibody.
     Antiviral Res. 2023;211:105546.
     PubMed     Abstract available
     
     
     December 2022
163. SPENGLER JR, Welch SR, Deval J, Gentry BG, et al
     Meeting report: 35th international conference on antiviral research in Seattle, WA, USA - March 21-25, 2022.
     Antiviral Res. 2022 Dec 31:105521. doi: 10.1016/j.antiviral.2022.105521.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Influenza is free of charge.